文献速递胸部技术与安全MRPET

全身MRI与FDG-PET/CT在肺腺癌结外转移分期中的比较

Whole-body MRI versus fluorodeoxyglucose PET/CT for extra-nodal metastatic staging in lung adenocarcinoma.
PubMed 文献 · Eur J Radiol · 2026-06-11

本研究为前瞻性单中心研究,纳入69例活检证实的肺腺癌患者,比较全身MRI与FDG-PET/CT对结外转移病灶的检出效能。以组织病理或6个月随访影像为参考标准,全身MRI的敏感度显著高于FDG-PET/CT,两者特异度相当。全身MRI无电离辐射且单例费用约为FDG-PET/CT的三分之一。

要点

  • 全身MRI检出278个病灶,多于FDG-PET/CT的260个病灶
  • 全身MRI敏感度95.10%,显著高于FDG-PET/CT的91.85%(p<0.001)
  • 全身MRI单例费用148欧元,明显低于FDG-PET/CT的442欧元

核心结论

  • 全身MRI对肺腺癌结外转移分期的诊断准确性与FDG-PET/CT相当,且具有无电离辐射和费用显著更低的优势

研究设计与样本

  • 前瞻性单中心研究,纳入70例活检证实的肺腺癌患者,最终69例纳入分析(排除1例黏液腺癌)
  • 所有患者均接受3T全身MRI与FDG-PET/CT用于初始分期,平均年龄55.8±13.1岁,其中男性46例
  • 参考标准为组织病理学或6个月随访影像,40例有转移,29例无转移(真阴性),配对比较采用McNemar检验

关键影像表现/征象

  • 全身MRI共检出278个病灶,FDG-PET/CT共检出260个病灶,全身MRI检出病灶数更多
  • 两种检查方式间一致性几乎完美,κ=0.91

诊断标准与关键数值

  • 全身MRI敏感度95.10%(95%CI:91.95-97.06%),特异度95.57%(95%CI:92.42-97.45%),准确性95.33%(95%CI:93.25-96.79%)
  • FDG-PET/CT敏感度91.85%(95%CI:87.97-94.56%),特异度95.65%(95%CI:92.56-97.50%),准确性93.77%(95%CI:91.42-95.51%)
  • 全身MRI敏感度显著高于FDG-PET/CT(McNemar检验,p<0.001),特异度差异无统计学意义(p=0.074)
  • 全身MRI单例费用148欧元(16000印度卢比),FDG-PET/CT单例费用442欧元(48000印度卢比)

临床应用与阅片要点

  • 全身MRI可作为肺腺癌结外转移分期的可行选择,尤其适用于需避免电离辐射的患者
  • 阅片时注意全身MRI检出病灶数可能多于FDG-PET/CT,但两者一致性高(κ=0.91)
  • 在资源受限或成本敏感场景下,全身MRI的费用优势可能影响检查方式选择

局限性

  • 单中心前瞻性研究,样本量69例
  • 以6个月随访影像作为部分病灶的参考标准,可能影响诊断准确性评估

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the diagnostic accuracy and cost-effectiveness of whole-body magnetic resonance imaging (WB-MRI) versus 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for detecting extra-nodal metastatic lesions in lung adenocarcinoma.

MATERIALS AND METHODS: This prospective single-centre study enrolled 70 patients with biopsy-proven lung adenocarcinoma who underwent FDG-PET/CT and WB-MRI (3 T) for initial staging; one patient was excluded (mucinous adenocarcinoma). The final cohort comprised 69 patients (mean age 55.8 ± 13.1 years, 46 men): 40 with metastatic disease and 29 without (true negatives). Sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and inter-modality agreement were calculated at lesion level against histopathology or six-month follow-up imaging. Paired comparisons used McNemar's test.

RESULTS: Sixty-nine patients (mean age 55.8 ± 13.1 years, 46 men) were evaluated. WB-MRI detected 278 lesions versus 260 for FDG-PET/CT. WB-MRI achieved sensitivity of 95.10 % (95 % CI: 91.95-97.06 %), specificity of 95.57 % (95 % confidence interval (CI): 92.42-97.45 %), and accuracy of 95.33 % (95 % CI: 93.25-96.79 %). FDG-PET/CT achieved sensitivity of 91.85 % (95 % CI: 87.97-94.56 %), specificity of 95.65 % (95 % CI: 92.56-97.50 %), and accuracy of 93.77 % (95 % CI: 91.42-95.51 %). WB-MRI sensitivity was significantly higher than FDG-PET/CT (McNemar's test, p < 0.001); specificity was equivalent (p = 0.074). Inter-modality agreement was almost perfect (κ = 0.91). WB-MRI cost 148 Euro (16,000 Indian Rupee [INR]) per patient versus 442 Euro (48,000 INR) for FDG-PET/CT.

CONCLUSION: WB-MRI demonstrates diagnostic accuracy equivalent to FDG-PET/CT for extra-nodal metastatic staging in lung adenocarcinoma, with the additional advantages of no ionising radiation and substantially lower cost.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Khoda, Niranjanamurthy, Gupta, et al. Whole-body MRI versus fluorodeoxyglucose PET/CT for extra-nodal metastatic staging in lung adenocarcinoma. Eur J Radiol. 2026. PMID: 42302437. doi:10.1016/j.ejrad.2026.113003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。